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EU-U.S.Beef Hormone Trade Dispute
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515-294-5811
This article provides a briefhistorical perspective of thebeef hormone dispute be-
tween the European Union (EU) and
the United States and reviews the
scientific evidence of health risks
associated with products from
animals that have been admnistered
hormones.
HISTORICAL BACKGROUND
In the 1980s, the EU passed a set
of regulations prohibiting the admin-
istration of some natural and syn-
thetic growth hormones to farm
animals. The same regulations also
banned the marketing of domestic
and imported meat derived from
animals having received these types
of hormones.
In 1996, the EU updated the
regulations on hormones to pro-
hibit the marketing or importing of
meat products obtained from
animals having received hormonal
or thyrostastic action.  Included
were the six hormones that were
the subject of a trade dispute
between the EU and the United
States (joined by Canada).
The six hormones at issue were
oestradiol-17b, progesterone,
testosterone, which are all natural
substances, and trenbolone acetate,
zeranol, and melengestrol acetate
(MGA), which are synthetic. The
same regulations permitted EU-
member states (only) to use the
three natural hormones and other
substances with hormonal action
for medical and zootechnical
reasons.  Also, market meat from
animals that had been fed these
substances was permitted.
In 1996 the United States and
Canada brought separate but similar
complaints to the World Trade
Organization (WTO), claiming that
the EU regulations were in contradic-
tion with the principles of the WTO
agreements. In the summer of 1997, a
WTO panel assembled to resolve the
U.S. and Canadian disputes con-
cluded that the EU regulations were
inconsistent with some articles of the
Agreement on Sanitary and
Phytosanitary (SPS) Measures, which
was signed by all WTO members in
Marrakech in 1994.
Specifically, the WTO panel
concluded that the EU regulations
were not based on risk assessment.
The regulations used arbitrary
distinctions in levels of sanitary
protection considered appropriate,
which resulted in trade restriction.
Furthermore, the inconsistency of
EU regulations with international
standards was not justified. The
panel recommended that the Dis-
pute Settlement Body ruling on the
dispute request the EU to bring its
regulations into conformity with the
SPS agreement.
In September 1997, the EU
initiated an appeal to the panel’s
conclusions as an appellant.  The
United States and Canada filed as
appelees. The EU contended that the
WTO panel erred in using the argu-
ment of inconsistency with interna-
tional standards because the
Agreement on SPS Measures does
explicitly recognize a country’s right
to set its own standards.
The EU also disagreed with the
panel on the burden of proof of the
lack of health effects of growth
hormones.  It claimed that the panel
had imposed its own assessment of
the scientific evidence and refused
the EU precautionary approach to
health risk, especially for cancer risk
related to the use of the hormone
MGA. The EU argued that the SPS
agreement allowed countries to
exceed international standards and
that harmonization to international
standards was not implied by the
agreement. Another argument cited
by the EU was the risk arising from
the lack of sound veterinary practice
and that the EU should have the
prerogative to assess if an exporting
member has sufficient veterinary
control measures to insure health
protection in the EU.
As an appelee, the United States
responded that the issue at stake
was not the way the risk assessment
had been conducted or how risk
averse the EU could be with a
precautionary stance. The issue was
rather that the EU had imposed the
trade ban without risk assessment.
Furthermore, the United States
An important question induced
by the hormone trade dispute is:
How safe are growth hormones?
Based on more than 30 years of
hormone use in the United
States, there is no evidence of
hormone residues in meat ex-
ceeding recommended stan-
dards, or of adverse human
health effects coming from this
process attribute of beef.
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argued that WTO agreements apply
to all regulations in member coun-
tries, including past regulations. The
appelate body reached a similar
conclusion to the original ruling,
although it corrected some conclu-
sions of the original panel. Accord-
ing to the appellate body, the EU ban
was inconsistent with WTO prin-
ciples, specifically with the SPS
agreement because it was not based
on risk assessment.
Following the appellate body
ruling, the EU filed for arbitration,
which is a last-resort means to
contest or soften a ruling. The
arbitrator had consultations in early
1998 and eventually ruled that the
reasonable period of time for the EU
to comply with the ruling of the
appellate body was 15 months from
the date of the ruling (February 28,
1998).  By then, the EU’s regulations
were to be consistent with the WTO
Agreement on SPS Measures. The
arbitrator rejected the latter request
because it was not prompt and not a
preferred way to eliminate the
inconsistency with the SPS agree-
ment relative to a simple withdrawal
of the EU regulation.
At the end of April 1999, the EU
announced it would not be able to
comply on time with the arbitrator’s
ruling and would consider offering
compensation. Now that the 15-
month period has expired, the United
States and Canada have been autho-
rized to impose punitive tariffs on
selected imports from the EU. In mid-
July, the United States announced it
would impose 100 percent duties on
$116.8 million of EU exports because
of th EU’s failure to comply with the
WTO ruling.
How well does the WTO’s dis-
pute settlement mechanism work?
First of all, resolution of the EU-U.S.
trade dispute took a long time.
Initiated in 1996, the beef dispute is
still not effectively resolved, and it
may still lead to a trade war between
the United States and the EU.
Many economists and policy
experts have criticized the aggres-
sive stance of the United States
when it attempts to open foreign
markets using section 301 of the
1974 U.S. trade law. Section 301 uses
the mercantilist stick of threats of
trade sanction to open foreign
markets, and until recently, it has
been considered a poor substitute
for the legal process of the dispute
settlement mechanism under the
WTO. Now it appears that the United
States and the EU may have reached
the same “threat game.” This is a
real test for the WTO, which has to
show it has teeth to the world
trading community to keep its
credibility. Assuming that the WTO
survives this EU-U.S. trade crisis on
hormone-fed beef, a bigger challenge
awaits the WTO with trade involving
genetically modified organisms.
PROTECTING CONSUMER INTEREST
Another issue raised by the
hormone dispute is the choice of
appropriate policy instrument to use
to intervene in markets and protect
consumer interest. Except for emer-
gency situations, economists tend to
dislike bans because they restrict
consumers’ quality choice. Some
consumers simply do not care about
the process attributes of products,
that is, the way they have been
produced. What policy options could
be considered beyond a ban on
hormone-fed animal products?
Labeling is a first option. Meat
could be labeled indicating the
process attributes of the meat, for
example, the type of feed and drugs
administered to the animal. Then the
market forces would determine a
price premium if enough consumers
valued “hormone-free” meat prod-
ucts higher than meat coming from
hormone-fed animals. Such a label-
ing scheme could be costly to
implement because it is difficult to
identify meat from animals that
received growth hormones. The
labeling scheme would require
identity through the food chain, i.e.,
tracking the animals at the farm and
monitoring the feeding process to
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insure that no hormonal additive has
been administered.
Another option would be to set
standards limiting hormone residues
in meat products to safe or precau-
tionary levels and to impose a ban
when the standards were violated.
Such standards are already defined
by an international institution, such
as the Codex Commission, which is
shielded from direct political influ-
ence. The latter instrument raises
the issue of harmonization of stan-
dards. Some countries may not
agree with international standards
as was the case with the EU. Harmo-
nization goes against the presump-
tion of most economists that
harmonization of standards among
heterogeneous trade partners with
different tastes is not optimal.
Hence, in practice, finding accept-
able standards may be difficult.
An important question induced
by the hormone trade dispute is:
How safe are growth hormones?
Based on more than 30 years of
hormone use in the United States,
there is no evidence of hormone
residues in meat exceeding recom-
mended standards, or of adverse
human health effects coming from
this process attribute of beef. For
most hormones, the absence of
health consequences hinges on
good veterinary and animal hus-
bandry practices in hormone use.
These good practices imply that
hormone residues are minimal and
correspond to naturally occurring
hormone residues levels present in
animal products. Hormones, both
natural and synthetic, tend to have
short half-lives, in the order of a few
days. This means their concentra-
tion decreases by half within a few
days and to nearly undetectable
levels within a few weeks. Deviations
from these good practices, such as
overdose, late injection, or improper
injection forms, can have adverse
health consequences. Hormones do
have health consequences and can
be carcinogenic at high dosages.
Hence, control and producer educa-
tion on appropriate procedures
appear to be essential components
of a well-functioning system. t
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One thing seems certain: weare now familiar with yetanother acronym.  GMO
stands for genetically modified
organism and designates a living
entity (such as a bacterium, plant, or
animal) whose genome has been
modified by recombinant DNA
technology.  The ability to alter the
genetic makeup of organisms directly
by such methods (i.e., transgenic)
constitutes the hallmark of modern
biotechnology and has ushered in a
new era in agricultural research.
The promises of biotechnology in
agriculture have at last begun to be
realized, and in recent years an
increasing stream of transgenic
plants have been approved and
marketed mostly (but not only) in the
United States.  Two such crops now
well known to midwestern farmers
are Roundup Ready (RR) soybeans
and Bt corn.   For RR crops, the
relevant genetic material comes from
a particular strain of Agrobacterium
that, once introduced into the plant,
confers resistance to glyphosate
herbicide.  For Bt crops, the genetic
material of interest comes from
another bacterium, Bacillus
thuringiensis; once inserted into
maize, it confers to the plant the
ability to kill the European corn borer.
ACCEPTANCE OF GMOS
The GMOs, by and large, have
been welcomed by U.S. agriculture
and by a number of other countries
(notably Canada and Argentina).
These new crops were virtually
unknown before 1996 but have
experienced breathtaking adoption
rates.  For example, in 1999 more
than 50 percent of the soybean crop
grown in the United States is geneti-
cally modified (at least 40 percent of
U.S. corn and about 40 percent of
U.S. cotton are also transgenic).  For
the next crop year it is estimated
that 100 percent of the soybeans
grown in Argentina will be herbicide
resistant.  But GMOs have struck a
different cord in Europe, where they
have met with numerous obstacles
from consumers, businesses,
policymakers, and regulators.
Safe food is at issue.  Transfer-
ring genetic material from one
organism to a completely different
one is perceived by some as unnatu-
ral, and it is feared that the presence
of a foreign genetic code may induce
the transformed organism to pro-
duce unwanted toxins and allergens.
The absence of risk from eating such
food, it is claimed, has not been
adequately documented.
